Single-dose vaccine may be effective for Covid-19 survivors

For the study, the team conducted a survey of 1,090 healthcare workers at Cedars-Sinai who had received the Pfizer-BioNTech vaccine.

The study from Pfizer-BioNTech says the vaccine remains highly effective after six months and retains efficacy against the B.1351 variant first detected in South Africa.

Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, agreed that protection from these vaccines is likely to last longer than six months.

A second study, the largest study on antibody and cellular immune factors to date, suggests people are likely to be protected against the Wuhan, Kent and Brazilian types of coronavirus following two doses of the Pfizer jab.

The updated data from a trial of more than 46,000 participants through March 13 showed 927 confirmed symptomatic cases of COVID-19.

The firms said that of these cases, 850 occurred among participants who got the placebo, while 77 were in the vaccinated group.

COVID-19: Ford government pulling 'emergency brake'
Oshawa will be back under an emergency lockdown, along with the rest of the province, effective Saturday, April 3 at 12:01 a.m. Outdoor public events and social gatherings must comply with public health advice and have no more than five people.

Fully vaccinated people who are traveling internationally do not need to be tested for COVID-19 before leaving the United States unless their destination requires them to be, and they do not need to self-quarantine upon arriving in the country, federal health officials said.

The companies said the results contained data on more than 12,000 participants who had been fully inoculated for at least six months.

The antibody response in these people remained 28-fold higher even after the second vaccine dose.

Professor Paul Moss, from the University of Birmingham and leader of the UK Coronavirus Immunology Consortium, told a briefing he was surprised how well the vaccines have worked in older people.

"The antibody levels were so high that they'd gone above the thresholds so they had to dilute them".

Bourla said the company planned to seek emergency authorization from the US Food and Drug Administration "in the coming weeks and to other regulators around the world, with the hope of starting to vaccinate this age group before the start of the next school year".